Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 2, 2009 - Issue 6
Submit an article Journal homepage
205
Views
18
CrossRef citations to date
0
Altmetric
Drug Profile

Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

Ronald Christopher Takeda San Diego, Inc., 10410 Science Center Drive, San Diego, CA 92121, USA. [email protected]
&
Aziz Karim Takeda Global Research & Development, Inc., 675 North Field Drive, Lake Forest, IL 60045, USA. [email protected]
Pages 589-600 | Published online: 10 Jan 2014

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now

Articles from other publishers (17)

Manal S. Elmasry, Wafaa S. Hassan, Hanan A. Merey & Israa M. Nour. (2023) Earth-friendly micellar UPLC technique for determination of four hypoglycemic drugs in different pharmaceutical dosage forms and spiked human plasma. BMC Chemistry 17:1.
Crossref
Shuangshuang Zhang, Ruixue Gan, Ludan Zhao, Qiaomei Sun, Hongzhao Xiang, Xi Xiang, Gang Zhao & Hui Li. (2021) Unveiling the interaction mechanism of alogliptin benzoate with human serum albumin: Insights from spectroscopy, microcalorimetry, and molecular docking and molecular dynamics analyses. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 246, pages 119040.
Crossref
João Pedro Ferreira, Cyrus Mehta, Abhinav Sharma, Steven E. Nissen, Patrick Rossignol & Faiez Zannad. (2020) Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. BMC Medicine 18:1.
Crossref
Sri Nagarjun Batchu, Veera Ganesh Yerra, Youan Liu, Suzanne L. Advani, Thomas Klein & Andrew Advani. (2020) The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans. International Journal of Molecular Sciences 21:16, pages 5756.
Crossref
Maolin Yang & Pingyu Jiang. (2019) Socialized and self-organized collaborative designer community-resilience modeling and assessment. Research in Engineering Design 31:1, pages 3-24.
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Nesrine T. Lamie & Marianne A. Mahrouse. (2018) Smart spectrophotometric methods based on normalized spectra for simultaneous determination of alogliptin and metformin in their combined tablets. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 204, pages 743-747.
Crossref
Wafaa A. Zaghary, Shereen Mowaka, Mostafa A. Hassan & Bassam M. Ayoub. (2017) Comparative study between different simple methods manipulating ratio spectra for the analysis of alogliptin and metformin co-formulated with highly different concentrations. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 186, pages 23-28.
Crossref
Himanshu Naik, Richard Czerniak & Majid Vakilynejad. (2016) Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin. British Journal of Clinical Pharmacology 81:4, pages 700-712.
Crossref
Nina Aleksandrovna Petunina & Anna Leont'evna Terekhova. (2014) Alogliptin – the new member of DPP-4 inhibitors class. Obesity and metabolism 11:4, pages 25-31.
Crossref
T. M. E. Davis. (2014) Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes, Obesity and Metabolism 16:10, pages 891-899.
Crossref
Uche Anadu NdefoOkwuchukwu OkoliGoldina Erowele. (2014) Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. American Journal of Health-System Pharmacy 71:2, pages 103-109.
Crossref
Larry K. Golightly, Caitlin C. Drayna & Michael T. McDermott. (2012) Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. Clinical Pharmacokinetics 51:8, pages 501-514.
Crossref
E. J. Verspohl. (2012) Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews 64:2, pages 188-237.
Crossref
Kohei Kaku, Masashi Hirayama & Emiko Komura. (2012) Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus. Combination Products in Therapy 2:1.
Crossref
Joanne Bronson, Murali Dhar, William Ewing & Nils Lonberg. 2011. 433 502 .
A. J. Scheen. (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, Obesity and Metabolism 12:8, pages 648-658.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.